Synergy CHC prices $4.375 million public offering of common stock

WESTBROOK, Maine - Synergy CHC Corp. (NASDAQ:SNYR) announced on Monday the pricing of an underwritten public offering of 1,750,000 shares of common stock at $2.50 per share, expected to generate gross proceeds of $4.375 million before deducting underwriting discounts, commissions, and other expenses. The offering price represents a slight discount to the current market price of $2.92, with InvestingPro data showing the stock has seen a significant return of 145% over the past year despite recent market volatility.

The consumer health and wellness company has granted underwriters a 45-day option to purchase up to an additional 262,500 shares at the public offering price less underwriting discounts and commissions.

Scheduled to close on Wednesday, August 27, the offering will provide funds for working capital and general corporate purposes, according to the company’s statement. As part of the arrangement, Synergy has agreed to issue warrants to the underwriter for up to 52,500 shares of common stock, which will be exercisable beginning 180 days after closing.

Bancroft Capital, LLC is serving as the sole book-running manager for the offering, which follows the SEC’s declaration of effectiveness for Synergy’s registration statement on August 25.

Synergy CHC Corp. markets consumer health products including its flagship brands FOCUSfactor and Flat Tummy. The company’s products are distributed through major retailers including Costco, Walmart, Amazon, and Walgreens in the U.S., Canada, and the U.K. According to InvestingPro analysis, the company maintains impressive gross profit margins of 70% and trades at an attractive P/E ratio of 8.4. For deeper insights into Synergy’s financial health and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.

The information in this article is based on a press release statement from the company.

In other recent news, Synergy CHC Corporation reported a strong second quarter for 2025, demonstrating significant improvements in its financial performance. The company achieved a net income increase of 125% compared to the previous year, with net revenue reaching $8.1 million, marking a 1% rise. These results highlight the company’s robust profitability growth. Despite these positive financial metrics, there was a slight dip in stock price during pre-market trading. Synergy CHC remains optimistic about its future growth, particularly with planned international expansions. There were no significant mergers or acquisitions reported in this period. Analyst opinions or changes in stock ratings were not mentioned in the recent updates. The company continues to focus on strategic expansions to bolster its market presence.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.